Skip to main content
. 2021 Feb 16;5(4):bvab019. doi: 10.1210/jendso/bvab019

Figure 3.

Figure 3.

Utility at baseline and following treatment with metreleptin in patients with generalized and partial lipodystrophy. This figure presents the quality-adjusted life year gains associated with 12 months of treatment with metreleptin, estimated at 0.313 for generalized lipodystrophy and 0.117 for partial lipodystrophy, reducing the gap in quality of life between untreated lipodystrophy and perfect health by approximately 59% and 31%, respectively.